Remdesivir for the treatment of Covid-19—preliminary report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
[HTML][HTML] Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics
B Chatterjee, SS Thakur - Frontiers in Immunology, 2022 - frontiersin.org
The SARS-CoV-2 virus needs multiple copies for its multiplication using an enzyme RNA-
dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the …
dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the …
Compassionate use of remdesivir for patients with severe Covid-19
J Grein, N Ohmagari, D Shin, G Diaz… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA
polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided …
polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided …
Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience
A Russo, E Binetti, C Borrazzo, EG Cacciola… - Journal of clinical …, 2021 - mdpi.com
Objectives: Remdesivir is currently approved for the treatment of COVID-19. The
recommendation for using remdesivir in patients with COVID-19 was based on the in vitro …
recommendation for using remdesivir in patients with COVID-19 was based on the in vitro …
Greek Remdesivir Cohort (GREC) study: effectiveness of antiviral drug remdesivir in hospitalized patients with COVID-19 pneumonia
In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery
period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as …
period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as …
[HTML][HTML] Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital …
M Lucijanić, N Bušić, P Bistrović, I Papić… - Croatian medical …, 2022 - ncbi.nlm.nih.gov
Aim To evaluate the association of remdesivir use and the survival of hospitalized patients
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …
Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay
J Figueredo, LF Lopez, BF Leguizamon… - BMC Infectious …, 2024 - Springer
Background The health crisis due to Covid-19 led to the search for therapeutics that could
improve the evolution of the disease. Remdesivir, an antiviral that interferes with viral …
improve the evolution of the disease. Remdesivir, an antiviral that interferes with viral …
Remdesivir use in patients requiring mechanical ventilation due to COVID-19
G Lapadula, DP Bernasconi, G Bellani… - Open forum …, 2020 - academic.oup.com
Background Remdesivir has been associated with accelerated recovery of severe
coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients …
coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients …
Remdesivir is effective for moderately severe patients: a re-analysis of the first double-blind, placebo-controlled, randomized trial on remdesivir for treatment of severe …
Introduction: The first clinical trial on remdesivir for treatment of severe COVID-19 conducted
in China was terminated prematurely due to limited patient enrollment, which rendered the …
in China was terminated prematurely due to limited patient enrollment, which rendered the …
[HTML][HTML] Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
S Ide, S Saito, T Akazawa, T Furuya, J Masuda… - IDCases, 2021 - Elsevier
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment
and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis …
and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis …